Overexpression of p53 in extra large (more than 10 cm) hepatocellular carcinoma

  • Toar J.M. Lalisang Department of Surgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta
  • Yefta Moenadjat Department of Surgery, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta
  • Nurjati C. Siregar Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta
  • Marini Stephanie Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta
DOI: https://doi.org/10.13181/mji.v27i2.1980
Keywords: HCC, p53, poorly differentiated tumor, tumor size
Abstract viewed: 1166 times
PDF downloaded: 706 times
HTML downloaded: 84 times
EPUB downloaded: 151 times

Abstract

Background: Extra large hepatocellular carcinoma (HCC) of >10 cm managed in our center shows a specific characteristic in tropical regions. This type of HCC exhibits distinct p53 expression. This study aimed to determine the association between p53 expression and tumor size and behavior.

Method:Subjects with HCC who underwent surgical resection in our hospital during 2012–2015 were enrolled in this study. Subject’s characteristics, tumor size, histopathology findings, and tumor behavior were variables observed. An immunohistochemical study on p53 expression was conducted to determine its association with those variables.

Results:This study involved 38 subjects with tumor size ranging from 3 cm to 25 cm in diameter and 20 subjects (52.8%) with tumor size ranging from 10 cm to 25 cm in diameter. Only 13 samples were evaluated for p53 expression. Five subjects with >10 cm (extra large) tumor showed highly/overexpressed p53 (intensity>50%), two subjects with strong p53 expression (intensity>5%–50%), and two subjects with weak expression. Three subjects with <10 cm (large) tumor showed strong expression of p53 (5%–9%) and a subject with 3 cm tumor showed weak p53 expression (<5%). Highly expressed p53 was found in patients with microvascular invasion, inflammatory response, mitosis, and necrosis.

Conclusion: Overexpression of p53 was associated with extra large and poorly differentiated HCC.

References

  1. Ruiz I, Féray C. Current management of hepatocellular carcinoma. Cancer Radiother. 2015;19(6-7):410-5. https://doi.org/10.1016/j.canrad.2015.05.008

  2. Han JH, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, et al. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol. 2014;20(45):17132-40. https://doi.org/10.3748/wjg.v20.i45.17132

  3. Truant S, Boleslawski E, Duhamel A, Bouras AF, Louvet A, Febvay C, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012;38(12):1189-96. https://doi.org/10.1016/j.ejso.2012.07.112

  4. Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122(22):3430-46. https://doi.org/10.1002/cncr.30237

  5. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 2009;15(5):513-20. https://doi.org/10.3748/wjg.15.513

  6. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56(1):267-75. https://doi.org/10.1016/j.jhep.2011.07.007

  7. Zhou T, Ye L, Bai Y, Sun A, Cox B, Liu D, et al. Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog. PLoS One. 2014;9(9):e107876. https://doi.org/10.1371/journal.pone.0107876

  8. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1(5):a001883. https://doi.org/10.1101/cshperspect.a001883

  9. Kunst C, Haderer M, Heckel S, Schlosser S, Müller M. The p53 family in hepatocellular carcinoma. Transl Cancer Res. 2016;5(6):632-8. https://doi.org/10.21037/tcr.2016.11.79

  10. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-17. https://doi.org/10.1016/j.ccr.2014.01.021

  11. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15(Supplement 4):14-22. https://doi.org/10.1634/theoncologist.2010-S4-14

  12. Liu J, Li W, Deng M, Liu D, Ma Q, Feng X. Immunohistochemical determination of p53 protein overexpression for predicting p53 gene mutations in hepatocellular carcinoma: a meta-analysis. PLoS One. 2016;11(7):e0159636. https://doi.org/10.1371/journal.pone.0159636

  13. Yang XD, Pan LH, Wang L, Ke Y, Cao J, Yang C, et al. Systematic review of single large and/or multinodular hepatocellular carcinoma: surgical resection improves survival. Asian Pac J Cancer Prev. 2015;16(13):5541-7. https://doi.org/10.7314/APJCP.2015.16.13.5541

  14. Zhong JH, Rodríguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine. 2015;94(3):e396. https://doi.org/10.1097/MD.0000000000000396

  15. Zhan P, Ji YN. Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr. 2014;3(1):11-7.

  16. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8(3):459-63. https://doi.org/10.3748/wjg.v8.i3.459

  17. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22(56):9030â40. https://doi.org/10.1038/sj.onc.1207116

  18. Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. P53 on the crossroad between regeneration and cancer. Cell Death Differ. 2017;24(1):8-14. https://doi.org/10.1038/cdd.2016.117

  19. Jiang P, Du W, Heese K, Wu M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol. 2006;26(23):9071-82. https://doi.org/10.1128/MCB.01025-06

  20. Guan YS, He Q, La Z. Roles of p53 in carcinogenesis, diagnosis and treatment of hepatocellular carcinoma. J Cancer Mol. 2006;2(5):191-7.

  21. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87(2):227-47. https://doi.org/10.1007/s00204-012-0931-2

  22. Graur F, Furcea L, Mois E, Biliuta A, Rozs AT, Negrean V, et al. Analysis of p53 protein expression in hepatocellular carcinoma. J Gastrointestin Liver Dis. 2016;25(3):345-9.

  23. Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, et al. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of FISHing c-myc gene for early relapse. PLoS One. 2013;8(7):e68203. https://doi.org/10.1371/journal.pone.0068203

  24. Cioca A, Cimpean AM, Kundnani NR, Ceausu R, Suciu C, Raica M. P53 expression as a prognostic marker in hepatocellular carcinoma. Arch Biol Sci. 2014;66(2):841-5. https://doi.org/10.2298/ABS1402841C

  25. Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int. 2014;2014:153867. https://doi.org/10.1155/2014/153867

Published
2018-09-09
How to Cite
1.
Lalisang TJ, Moenadjat Y, Siregar NC, Stephanie M. Overexpression of p53 in extra large (more than 10 cm) hepatocellular carcinoma. Med J Indones [Internet]. 2018Sep.9 [cited 2024Apr.25];27(2):71–75. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/1980
Issue
Vol. 27 No. 2 (2018): June
Section
Basic Medical Research

Copyright (c) 2018 Toar J.M. Lalisang, Yefta Moenadjat, Nurjati C. Siregar, Marini Stephanie

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.